Neurogene

Focus: Neurogene is a New York-based biotech company focused on genetic therapies for rare neurological and genetic diseases. The company operates in a highly specialized segment with a pipeline targeting ultra-rare indications.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Neurogene

AI assessmentNot Hiring

No open roles listed right now. Follow Neurogene to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

Ceroid Lipofuscinosis, Neuronal 5

N/A

Clinical Trials (1)

NCT03822650A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)

N/A

Help build intelligence for Neurogene

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a clinical-stage pipeline with Phase 3 momentum: NGN-401 for Rett Syndrome is the most advanced program, offering visibility into a major newsflow event
Work in cutting-edge gene therapy for ultra-rare diseases with high unmet medical need and favorable regulatory pathways (rare disease designations enable accelerated approval tracks)
Join a focused team in a nascent modality where scientific expertise and execution excellence directly drive company and career trajectory

Watch Out For

No active hiring listed (0 open roles) suggests limited near-term career entry points or potential restructuring
Pre-revenue status with unknown funding and employee count creates cash runway uncertainty and compensation/equity risk

Generated by Claude from Neurogene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)

Charcot-Marie-Tooth Disease

N/A

Clinical Trials (1)

NCT03810508A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)

N/A

A Natural History Study of Aspartylglucosaminuria

Aspartylglucosaminuria

N/A

Clinical Trials (1)

NCT03853876A Natural History Study of Aspartylglucosaminuria

N/A